ANNOVIS BIO INC. COMMON STOCK

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

14 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

07 يناير 2025 07:00:01 بحسب Nasdaq GlobeNewswire

Annovis to Host Year-End Investor Webcast on December 11, 2024

25 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

12 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

11 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

07 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

22 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs

15 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

03 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

02 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra

30 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

05 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Bio Reports Second Quarter Financial Results and Provides Business Update

15 أغسطس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

06 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

24 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

16 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team

09 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap

02 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap

27 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

26 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire